Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
| Distributed by / for | Heritage Pharmaceutical Inc., East Brunswick, NJ 08816 |
| NDC | 23155-645-03 |
| Full product label | Losartan Potassium Tablets USP 50 mg, a) 30 count (NDC 23155-645-03), b) 90 count (NDC 23155-645-09) and c) 1000 count (NDC 23155-645-10) bottles, Rx only, Manufactured by: Vivimed Life Sciences Private Limited, Tamil Nadu, India, Manufactured for: Heritage Pharmaceutical Inc., East Brunswick, NJ 08816 NDC 23155-645-09 |
| Recalling firm | Avet Pharmaceuticals, Inc. |
| Distribution | Nationwide |
| Quantity | a) 2,904; b) 14,316; c) 1,368 bottles |
| Recall initiated | 2020-03-26 |
| Report date | 2020-04-15 |
| Recall completed | 2021-03-08 |
| Recall number | D-1103-2020 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | East Brunswick NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗